Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

FDA Indictment of J&J Product Quality Suggests Gross, Cavalier Incompetence

|Includes: Johnson & Johnson (JNJ)

J&J, pressured by a two-week FDA audit at its Fort Washington, PA plant announced a store-wide recall of its children's liquid products under its Tylenol, Motrin, Zyrtec and Benadryl brands [http://www.fda.gov/Safety/Recalls/ucm210443.htm ].  The FDA issued a damning 17-page, 20-point 483 on May 4, 2010.  The cited deficiencies are gross, systemic and widespread and suggest a "screw-the-consumer" insouciance.  This recall of 44 sku's and 1,500 production lots is the fourth recall in seven months involving their key OTC brands.  The fact that these are products targeting infants makes it even more reprehensible.  J&J admits the impact of the recall will dent 2Q10 earnings.  On May 2nd The NY Times recognized damage to J&J brand equities [http://www.nytimes.com/2010/05/03/business/03drug.html?fta=y] reported months earlier by OTC Product News in January, 2010 [Safety of Brand Name Products Badly Damaged b...].  OTC/PN was prescient in calling out J&J's disregard for its brands and consumers early on.

Read more at: www.otcproductnews.com/otc-product-news/fda-indictment-of-jj-product-quality-suggests-gross-cavalier-incompetance.html



Disclosure: None